Literature DB >> 8123594

The properties of p53 proteins selected for the loss of suppression of transformation.

D C Olson1, A J Levine.   

Abstract

The wild-type p53 protein can act as a suppressor of transformation in that it will block or reduce the formation of adenovirus E1A plus ras mediated transformants of primary rat embryo fibroblasts (C. A. Finlay et al., Cell, 57: 1083-1093, 1989). In those experiments, all of the transformed cell lines that arose selected for mutations in the transfected p53 gene, and many of these cell lines now express mutant p53 proteins. These mutant p53 genes are unusual because they were selected only for their inability to act as a transformation suppressor of other oncogenes as opposed to mutant p53 genes that arise spontaneously in tumors or transformed cell lines. p53 mutants that arise in tumors may be selected for several properties, and these mutants do have a number of phenotypes in common; for example, (a) they no longer block the cell division of transformed cells in culture (growth suppressor); (b) they cooperate with ras to transform rat embryo cells; (c) they enhance the plating efficiency of rat embryo cells; (d) some mutants have an altered protein conformation; (e) most mutants have a much longer half-life and greater concentration in the cells; and (f) mutants have lost or have a reduced ability to act as a transcription factor. Experiments were carried out to test whether the selection for p53 mutants that fail to block oncogene mediated transformation would also have some or all of the other properties of p53 mutants that arise in spontaneous tumors. Two mutants selected for their lost ability to block transformation were cloned, sequenced, and tested for all of the phenotypes listed above. The properties that these mutants had in common were (a) cooperation with ras to transform cells, (b) enhanced plating efficiency of cells, (c) elevated steady-state expression levels, and (d) a lost or reduced ability to act as a transcription factor.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8123594

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  7 in total

Review 1.  Replication-selective adenoviruses as oncolytic agents.

Authors:  C Heise; D H Kirn
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

2.  Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo.

Authors:  E A Komarova; M V Chernov; R Franks; K Wang; G Armin; C R Zelnick; D M Chin; S S Bacus; G R Stark; A V Gudkov
Journal:  EMBO J       Date:  1997-03-17       Impact factor: 11.598

3.  Use of genetic suppressor elements to dissect distinct biological effects of separate p53 domains.

Authors:  V S Ossovskaya; I A Mazo; M V Chernov; O B Chernova; Z Strezoska; R Kondratov; G R Stark; P M Chumakov; A V Gudkov
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-17       Impact factor: 11.205

Review 4.  The role of transforming growth factor beta in glioma progression.

Authors:  M T Jennings; J A Pietenpol
Journal:  J Neurooncol       Date:  1998-01       Impact factor: 4.130

5.  A proliferative p53-responsive element mediates tumor necrosis factor alpha induction of the human immunodeficiency virus type 1 long terminal repeat.

Authors:  A Gualberto; M L Hixon; T S Finco; N D Perkins; G J Nabel; A S Baldwin
Journal:  Mol Cell Biol       Date:  1995-06       Impact factor: 4.272

Review 6.  Apoptosis in glioma cells: review and analysis of techniques used for study with focus on the laser scanning cytometer.

Authors:  Bardia Amirlak; William T Couldwell
Journal:  J Neurooncol       Date:  2003-06       Impact factor: 4.130

7.  Examining the key genes and pathways in hepatocellular carcinoma development from hepatitis B virus‑positive cirrhosis.

Authors:  Qi-Feng Chen; Jin-Guo Xia; Wang Li; Lu-Jun Shen; Tao Huang; Peihong Wu
Journal:  Mol Med Rep       Date:  2018-09-19       Impact factor: 2.952

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.